KPV

KPV exhibits potent anti-inflammatory effects by entering cells to inactivate inflammatory pathways such as NF-κB, reducing pro-inflammatory cytokines like TNF-α, IL-1β, and IL-6, and modulating immune responses.¹,²,³,⁴ It shows therapeutic promise in managing inflammatory bowel diseases including ulcerative colitis and Crohn's disease, where it promotes mucosal healing, restores gut barrier integrity, and decreases histological inflammation in animal models of DSS- and TNBS-induced colitis.²,³,⁴,⁵,⁶ Additional preclinical evidence supports its role in accelerating wound healing, combating microbial infections, and reducing inflammation in skin conditions like psoriasis.¹,²,³ Research remains primarily from animal studies and cell cultures, with limited human clinical data.¹

KPV, a derivative of alpha-melanocyte stimulating hormone, is generally well-tolerated with an excellent safety profile and rare, mild side effects across administration routes.⁷,⁸,⁹,¹⁰ Common side effects include gastrointestinal discomfort such as nausea, diarrhea, or vomiting (especially with oral forms), temporary skin reactions like redness or irritation (with topical use), and injection site reactions including pain, swelling, or redness (with subcutaneous injections).⁷,⁸,¹¹ Allergic reactions, though rare, can range from mild rash or hives to severe symptoms like swelling or difficulty breathing, requiring immediate medical attention.⁷,¹¹,¹² Unlike corticosteroids or NSAIDs, KPV does not suppress immune function, increase infection risk, or cause liver damage or tissue thinning.⁸,⁹,¹⁰ Key safety considerations include using it only under medical supervision, avoiding dose changes without approval, consulting for pre-existing conditions like bowel disease or active infections, and monitoring for persistent symptoms.⁷,¹⁰,¹² Limited human clinical data exists, so ongoing research is needed for long-term effects.⁹,¹²

KPV, a tripeptide derived from alpha-melanocyte stimulating hormone (alpha-MSH), exerts its primary anti-inflammatory effects by entering cells via the PepT1 transporter, bypassing cell surface receptors.¹³,¹⁴,¹⁵ Once inside, it accumulates in the nucleus and competitively binds to importin-alpha3, preventing the p65 subunit of NF-kB from translocating into the nucleus and activating pro-inflammatory genes.¹³,¹⁴ This stabilizes the NF-kB inhibitory protein IκBα, reducing its degradation and further blocking inflammatory signaling, while also suppressing cytokines such as IL-6, TNF-alpha, and IL-1beta.¹⁰,¹³,¹⁴ Additionally, KPV inhibits the MAPK pathway at low concentrations, though this may be secondary to NF-kB blockade.¹³ This receptor-independent mechanism distinguishes KPV from other anti-inflammatory peptides.¹³